Fig. 5: TRDMT1 inhibition sensitizes cells to radiation and PARPi.
From: m5C modification of mRNA serves a DNA damage code to promote homologous recombination
a Clinical and RNA-seq gene expression data were downloaded from TCGA. RSI was calculated by a rank-based linear regression algorithm. The median value of BRCA1 and TRDMT1 TPM was defined as the cutoff to classify patients into high expression and low expression groups (n = 1091, mean ±SD). b WT, TRDMT1 KO U2OS, or siBRCA1 cells were treated with Olaparib at the indicated dose. The survival rate was measured via the colony formation assay (n = 3, mean ± SEM). c Tumor volume in mice injected with LV-shTRDMT1 or LV-NC pre-treated MDA-MB-231 cells at the indicated time (n = 3, mean ± SEM). One week after injection, 50 mg/kg Olaparib or saline was intraperitoneally injected into the xenograft tumors once every other day. d Tumor volume in mice injected with LV-shTRDMT1 or LV-NC pre-treated MDA-MB-231 cells at day 12 after PARPi treatment (n = 3, mean ± SEM). Statistical analysis was performed with the unpaired two tailed Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
